Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $4.0 million.

  • Keros Therapeutics' Share-based Compensation fell 54.79% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year decrease of 7.29%. This contributed to the annual value of $34.9 million for FY2024, which is 21.24% up from last year.
  • As of Q3 2025, Keros Therapeutics' Share-based Compensation stood at $4.0 million, which was down 53.34% from $8.5 million recorded in Q2 2025.
  • Keros Therapeutics' Share-based Compensation's 5-year high stood at $9.2 million during Q4 2024, with a 5-year trough of $2.5 million in Q1 2021.
  • In the last 3 years, Keros Therapeutics' Share-based Compensation had a median value of $8.5 million in 2025 and averaged $7.7 million.
  • In the last 5 years, Keros Therapeutics' Share-based Compensation spiked by 20,683.33% in 2021 and then crashed by 54.79% in 2025.
  • Over the past 5 years, Keros Therapeutics' Share-based Compensation (Quarterly) stood at $3.3 million in 2021, then soared by 44.04% to $4.7 million in 2022, then spiked by 54.32% to $7.3 million in 2023, then rose by 25.61% to $9.2 million in 2024, then slumped by 54.79% to $4.0 million in 2025.
  • Its Share-based Compensation stands at $4.0 million for Q3 2025, versus $8.5 million for Q2 2025 and $8.9 million for Q1 2025.